Recent News

• 05.16.2025 - Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 05.16.2025 - Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 05.13.2025 - Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
• 05.13.2025 - Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
• 05.07.2025 - Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.07.2025 - Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
• 04.24.2025 - Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
• 04.24.2025 - Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
• 03.31.2025 - Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
• 03.31.2025 - Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Recent Filings

• 05.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.07.2025 - 8-K Current report
• 05.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.07.2025 - EX-99.1 EX-99.1
• 05.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.18.2025 - 8-K Current report
• 04.17.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.17.2025 - DEF 14A Other definitive proxy statements
• 04.17.2025 - ARS Annual Report to Security Holders
• 03.31.2025 - EFFECT Notice of Effectiveness